Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) colonizes multiple body sites, and carriage is an important risk factor for MRSA infection. Successful decolonization reduces disease incidence; however, decolonization protocols vary in the number of body sites targeted, and the impact of site-specific treatments is not well understood. Here, we used data from a randomized controlled trial (RCT) of MRSA decolonization using chlorhexidine body and mouth wash and nasal mupirocin to quantify the contribution of each treatment component to the success of the protocol. We estimated mouthwash as the least effective treatment component and the combined effect of MRSA clearance at the nares, skin, and wound as 93% (90% credible interval 85%-99%) of the full decolonization. Our model can estimate the effectiveness of hypothetical treatments in silico and shows enhancing MRSA clearance at nares will achieve the largest gains. This study demonstrates the use of machine learning to go beyond what is typically achieved by RCTs, facilitating evidence-based decision-making to streamline clinical protocols.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01209234
Clinical Protocols
https://doi.org/10.1056/NEJMoa1716771
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used the data from https://doi.org/10.1056/NEJMoa1716771. This trial was approved by the institutional review board of the University of California Irvine. For more details about the data collection, please see the original article https://doi.org/10.1056/NEJMoa1716771
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The CLEAR (Changing Lives by Eradicating Antibiotic Resistance) Trial demonstrated that the use of a post-discharge decolonization protocol in MRSA carriers reduces infection and hospitalization rates; ClinicalTrial.gov number NCT01209234, see reference https://doi.org/10.1056/NEJMoa1716771 for informed consent and institutional review board approvals. The data used in the present article is available on request from the corresponding author Susan Huang of the https://doi.org/10.1056/NEJMoa1716771, a co-author of this study.
